nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—RET—autonomic nervous system—Gilles de la Tourette syndrome	0.054	0.0618	CbGeAlD
Sorafenib—MUSK—nervous system—Gilles de la Tourette syndrome	0.0276	0.0317	CbGeAlD
Sorafenib—CDKL2—nervous system—Gilles de la Tourette syndrome	0.0225	0.0258	CbGeAlD
Sorafenib—CDKL2—central nervous system—Gilles de la Tourette syndrome	0.0217	0.0249	CbGeAlD
Sorafenib—MAPK15—nervous system—Gilles de la Tourette syndrome	0.0203	0.0232	CbGeAlD
Sorafenib—MAPK15—central nervous system—Gilles de la Tourette syndrome	0.0195	0.0224	CbGeAlD
Sorafenib—CDKL3—brain—Gilles de la Tourette syndrome	0.0188	0.0216	CbGeAlD
Sorafenib—CDKL2—brain—Gilles de la Tourette syndrome	0.0172	0.0197	CbGeAlD
Sorafenib—MAPK15—brain—Gilles de la Tourette syndrome	0.0155	0.0178	CbGeAlD
Sorafenib—MAPK11—nervous system—Gilles de la Tourette syndrome	0.012	0.0138	CbGeAlD
Sorafenib—CDK7—nervous system—Gilles de la Tourette syndrome	0.0118	0.0136	CbGeAlD
Sorafenib—AURKC—nervous system—Gilles de la Tourette syndrome	0.0117	0.0134	CbGeAlD
Sorafenib—MAPK11—central nervous system—Gilles de la Tourette syndrome	0.0116	0.0133	CbGeAlD
Sorafenib—CDK7—central nervous system—Gilles de la Tourette syndrome	0.0114	0.0131	CbGeAlD
Sorafenib—AURKC—central nervous system—Gilles de la Tourette syndrome	0.0112	0.0129	CbGeAlD
Sorafenib—BRAF—midbrain—Gilles de la Tourette syndrome	0.0109	0.0125	CbGeAlD
Sorafenib—EPHA6—nervous system—Gilles de la Tourette syndrome	0.0108	0.0124	CbGeAlD
Sorafenib—MUSK—Extracellular matrix organization—COL27A1—Gilles de la Tourette syndrome	0.0107	0.0838	CbGpPWpGaD
Sorafenib—HIPK4—brain—Gilles de la Tourette syndrome	0.0104	0.012	CbGeAlD
Sorafenib—EPHA6—central nervous system—Gilles de la Tourette syndrome	0.0104	0.0119	CbGeAlD
Sorafenib—ZAK—nervous system—Gilles de la Tourette syndrome	0.0102	0.0117	CbGeAlD
Sorafenib—ZAK—central nervous system—Gilles de la Tourette syndrome	0.00985	0.0113	CbGeAlD
Sorafenib—MAP3K19—nervous system—Gilles de la Tourette syndrome	0.00981	0.0112	CbGeAlD
Sorafenib—MAP3K19—central nervous system—Gilles de la Tourette syndrome	0.00944	0.0108	CbGeAlD
Sorafenib—TIE1—nervous system—Gilles de la Tourette syndrome	0.00936	0.0107	CbGeAlD
Sorafenib—FGFR1—midbrain—Gilles de la Tourette syndrome	0.00928	0.0106	CbGeAlD
Sorafenib—MAPK11—brain—Gilles de la Tourette syndrome	0.0092	0.0105	CbGeAlD
Sorafenib—CDK7—brain—Gilles de la Tourette syndrome	0.00905	0.0104	CbGeAlD
Sorafenib—TIE1—central nervous system—Gilles de la Tourette syndrome	0.00901	0.0103	CbGeAlD
Sorafenib—TAOK2—brain—Gilles de la Tourette syndrome	0.00898	0.0103	CbGeAlD
Sorafenib—AURKC—brain—Gilles de la Tourette syndrome	0.00891	0.0102	CbGeAlD
Sorafenib—MAP3K7—midbrain—Gilles de la Tourette syndrome	0.00879	0.0101	CbGeAlD
Sorafenib—MKNK2—midbrain—Gilles de la Tourette syndrome	0.00851	0.00976	CbGeAlD
Sorafenib—MKNK1—midbrain—Gilles de la Tourette syndrome	0.00841	0.00963	CbGeAlD
Sorafenib—RET—midbrain—Gilles de la Tourette syndrome	0.0083	0.00951	CbGeAlD
Sorafenib—EPHA6—brain—Gilles de la Tourette syndrome	0.00825	0.00945	CbGeAlD
Sorafenib—ZAK—brain—Gilles de la Tourette syndrome	0.00782	0.00896	CbGeAlD
Sorafenib—RALBP1—midbrain—Gilles de la Tourette syndrome	0.00769	0.00881	CbGeAlD
Sorafenib—HIPK3—brain—Gilles de la Tourette syndrome	0.00765	0.00877	CbGeAlD
Sorafenib—MAP3K19—brain—Gilles de la Tourette syndrome	0.0075	0.00859	CbGeAlD
Sorafenib—FLT1—midbrain—Gilles de la Tourette syndrome	0.00731	0.00838	CbGeAlD
Sorafenib—RAF1—midbrain—Gilles de la Tourette syndrome	0.00727	0.00833	CbGeAlD
Sorafenib—EPHB6—midbrain—Gilles de la Tourette syndrome	0.00723	0.00828	CbGeAlD
Sorafenib—RET—Dopaminergic Neurogenesis—SLC6A3—Gilles de la Tourette syndrome	0.00715	0.0562	CbGpPWpGaD
Sorafenib—TIE1—brain—Gilles de la Tourette syndrome	0.00715	0.0082	CbGeAlD
Sorafenib—MKNK2—nervous system—Gilles de la Tourette syndrome	0.007	0.00802	CbGeAlD
Sorafenib—MKNK1—nervous system—Gilles de la Tourette syndrome	0.00691	0.00792	CbGeAlD
Sorafenib—BRAF—brain—Gilles de la Tourette syndrome	0.00686	0.00786	CbGeAlD
Sorafenib—RET—nervous system—Gilles de la Tourette syndrome	0.00683	0.00782	CbGeAlD
Sorafenib—MKNK2—central nervous system—Gilles de la Tourette syndrome	0.00674	0.00772	CbGeAlD
Sorafenib—MKNK1—central nervous system—Gilles de la Tourette syndrome	0.00665	0.00762	CbGeAlD
Sorafenib—RET—central nervous system—Gilles de la Tourette syndrome	0.00657	0.00753	CbGeAlD
Sorafenib—EPHX2—brain—Gilles de la Tourette syndrome	0.00655	0.00751	CbGeAlD
Sorafenib—RALBP1—nervous system—Gilles de la Tourette syndrome	0.00632	0.00724	CbGeAlD
Sorafenib—MAP2K5—midbrain—Gilles de la Tourette syndrome	0.00618	0.00708	CbGeAlD
Sorafenib—KDR—midbrain—Gilles de la Tourette syndrome	0.00618	0.00708	CbGeAlD
Sorafenib—RALBP1—central nervous system—Gilles de la Tourette syndrome	0.00609	0.00697	CbGeAlD
Sorafenib—CSF1R—midbrain—Gilles de la Tourette syndrome	0.00603	0.00691	CbGeAlD
Sorafenib—FLT1—nervous system—Gilles de la Tourette syndrome	0.00601	0.00689	CbGeAlD
Sorafenib—RAF1—nervous system—Gilles de la Tourette syndrome	0.00598	0.00685	CbGeAlD
Sorafenib—EPHB6—nervous system—Gilles de la Tourette syndrome	0.00594	0.00681	CbGeAlD
Sorafenib—FLT4—brain—Gilles de la Tourette syndrome	0.00591	0.00677	CbGeAlD
Sorafenib—FGFR1—brain—Gilles de la Tourette syndrome	0.00583	0.00668	CbGeAlD
Sorafenib—FLT1—central nervous system—Gilles de la Tourette syndrome	0.00579	0.00663	CbGeAlD
Sorafenib—RAF1—central nervous system—Gilles de la Tourette syndrome	0.00575	0.00659	CbGeAlD
Sorafenib—EPHB6—central nervous system—Gilles de la Tourette syndrome	0.00572	0.00656	CbGeAlD
Sorafenib—STK10—nervous system—Gilles de la Tourette syndrome	0.00569	0.00652	CbGeAlD
Sorafenib—PDGFRA—nervous system—Gilles de la Tourette syndrome	0.00563	0.00646	CbGeAlD
Sorafenib—MAP3K7—brain—Gilles de la Tourette syndrome	0.00552	0.00632	CbGeAlD
Sorafenib—STK10—central nervous system—Gilles de la Tourette syndrome	0.00548	0.00628	CbGeAlD
Sorafenib—KIT—midbrain—Gilles de la Tourette syndrome	0.00548	0.00628	CbGeAlD
Sorafenib—PDGFRA—central nervous system—Gilles de la Tourette syndrome	0.00542	0.00621	CbGeAlD
Sorafenib—PDGFRB—midbrain—Gilles de la Tourette syndrome	0.00535	0.00613	CbGeAlD
Sorafenib—MKNK2—brain—Gilles de la Tourette syndrome	0.00535	0.00613	CbGeAlD
Sorafenib—MKNK1—brain—Gilles de la Tourette syndrome	0.00528	0.00605	CbGeAlD
Sorafenib—RET—brain—Gilles de la Tourette syndrome	0.00522	0.00598	CbGeAlD
Sorafenib—MAP2K5—nervous system—Gilles de la Tourette syndrome	0.00508	0.00582	CbGeAlD
Sorafenib—KDR—nervous system—Gilles de la Tourette syndrome	0.00508	0.00582	CbGeAlD
Sorafenib—CSF1R—nervous system—Gilles de la Tourette syndrome	0.00496	0.00568	CbGeAlD
Sorafenib—MAP2K5—central nervous system—Gilles de la Tourette syndrome	0.00489	0.00561	CbGeAlD
Sorafenib—KDR—central nervous system—Gilles de la Tourette syndrome	0.00489	0.00561	CbGeAlD
Sorafenib—RALBP1—brain—Gilles de la Tourette syndrome	0.00483	0.00554	CbGeAlD
Sorafenib—CSF1R—central nervous system—Gilles de la Tourette syndrome	0.00478	0.00547	CbGeAlD
Sorafenib—FLT1—brain—Gilles de la Tourette syndrome	0.0046	0.00527	CbGeAlD
Sorafenib—RAF1—brain—Gilles de la Tourette syndrome	0.00457	0.00523	CbGeAlD
Sorafenib—EPHB6—brain—Gilles de la Tourette syndrome	0.00454	0.0052	CbGeAlD
Sorafenib—HTR2C—midbrain—Gilles de la Tourette syndrome	0.00451	0.00517	CbGeAlD
Sorafenib—KIT—nervous system—Gilles de la Tourette syndrome	0.0045	0.00516	CbGeAlD
Sorafenib—PDGFRB—nervous system—Gilles de la Tourette syndrome	0.0044	0.00504	CbGeAlD
Sorafenib—STK10—brain—Gilles de la Tourette syndrome	0.00435	0.00498	CbGeAlD
Sorafenib—KIT—central nervous system—Gilles de la Tourette syndrome	0.00434	0.00497	CbGeAlD
Sorafenib—PDGFRA—brain—Gilles de la Tourette syndrome	0.00431	0.00493	CbGeAlD
Sorafenib—PDGFRB—central nervous system—Gilles de la Tourette syndrome	0.00424	0.00485	CbGeAlD
Sorafenib—KDR—brain—Gilles de la Tourette syndrome	0.00388	0.00445	CbGeAlD
Sorafenib—MAP2K5—brain—Gilles de la Tourette syndrome	0.00388	0.00445	CbGeAlD
Sorafenib—CSF1R—brain—Gilles de la Tourette syndrome	0.00379	0.00434	CbGeAlD
Sorafenib—HTR2C—nervous system—Gilles de la Tourette syndrome	0.00371	0.00425	CbGeAlD
Sorafenib—HTR2C—central nervous system—Gilles de la Tourette syndrome	0.00357	0.00409	CbGeAlD
Sorafenib—ABCC4—nervous system—Gilles de la Tourette syndrome	0.0035	0.00401	CbGeAlD
Sorafenib—HTR2B—nervous system—Gilles de la Tourette syndrome	0.00348	0.00399	CbGeAlD
Sorafenib—HTR2B—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.00345	0.0271	CbGpPWpGaD
Sorafenib—KIT—brain—Gilles de la Tourette syndrome	0.00344	0.00394	CbGeAlD
Sorafenib—ABCC4—central nervous system—Gilles de la Tourette syndrome	0.00337	0.00386	CbGeAlD
Sorafenib—PDGFRB—brain—Gilles de la Tourette syndrome	0.00336	0.00385	CbGeAlD
Sorafenib—HTR2B—central nervous system—Gilles de la Tourette syndrome	0.00335	0.00384	CbGeAlD
Sorafenib—RET—Posttranslational regulation of adherens junction stability and dissassembly—MET—Gilles de la Tourette syndrome	0.00301	0.0237	CbGpPWpGaD
Sorafenib—ABCG2—midbrain—Gilles de la Tourette syndrome	0.00301	0.00345	CbGeAlD
Sorafenib—CSF1R—Signaling events mediated by TCPTP—MET—Gilles de la Tourette syndrome	0.00289	0.0227	CbGpPWpGaD
Sorafenib—HTR2B—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00284	0.0223	CbGpPWpGaD
Sorafenib—HTR2C—brain—Gilles de la Tourette syndrome	0.00284	0.00325	CbGeAlD
Sorafenib—HTR2C—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.00278	0.0219	CbGpPWpGaD
Sorafenib—MAPK11—Parkinsons Disease Pathway—SLC6A3—Gilles de la Tourette syndrome	0.00272	0.0214	CbGpPWpGaD
Sorafenib—ABCC4—brain—Gilles de la Tourette syndrome	0.00268	0.00307	CbGeAlD
Sorafenib—HTR2B—brain—Gilles de la Tourette syndrome	0.00266	0.00305	CbGeAlD
Sorafenib—KDR—Extracellular matrix organization—COL27A1—Gilles de la Tourette syndrome	0.00254	0.02	CbGpPWpGaD
Sorafenib—HTR2B—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00243	0.0191	CbGpPWpGaD
Sorafenib—HTR2B—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00235	0.0185	CbGpPWpGaD
Sorafenib—HTR2C—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00229	0.018	CbGpPWpGaD
Sorafenib—HTR2B—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2A—Gilles de la Tourette syndrome	0.00229	0.018	CbGpPWpGaD
Sorafenib—CYP2B6—nervous system—Gilles de la Tourette syndrome	0.00228	0.00261	CbGeAlD
Sorafenib—CYP2B6—central nervous system—Gilles de la Tourette syndrome	0.0022	0.00252	CbGeAlD
Sorafenib—HTR2B—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00219	0.0172	CbGpPWpGaD
Sorafenib—RAF1—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2A—Gilles de la Tourette syndrome	0.00214	0.0168	CbGpPWpGaD
Sorafenib—HTR2B—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00204	0.016	CbGpPWpGaD
Sorafenib—HTR2B—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00198	0.0156	CbGpPWpGaD
Sorafenib—HTR2C—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00196	0.0154	CbGpPWpGaD
Sorafenib—CYP2C8—brain—Gilles de la Tourette syndrome	0.00194	0.00223	CbGeAlD
Sorafenib—HTR2C—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0019	0.0149	CbGpPWpGaD
Sorafenib—ABCG2—brain—Gilles de la Tourette syndrome	0.00189	0.00217	CbGeAlD
Sorafenib—KDR—Signaling events mediated by TCPTP—MET—Gilles de la Tourette syndrome	0.00186	0.0146	CbGpPWpGaD
Sorafenib—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2A—Gilles de la Tourette syndrome	0.00185	0.0145	CbGpPWpGaD
Sorafenib—HTR2B—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00184	0.0145	CbGpPWpGaD
Sorafenib—HTR2C—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00177	0.0139	CbGpPWpGaD
Sorafenib—CYP2B6—brain—Gilles de la Tourette syndrome	0.00174	0.002	CbGeAlD
Sorafenib—CYP3A4—nervous system—Gilles de la Tourette syndrome	0.00172	0.00197	CbGeAlD
Sorafenib—CYP2D6—nervous system—Gilles de la Tourette syndrome	0.00169	0.00194	CbGeAlD
Sorafenib—CYP3A4—central nervous system—Gilles de la Tourette syndrome	0.00166	0.0019	CbGeAlD
Sorafenib—HTR2C—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00164	0.0129	CbGpPWpGaD
Sorafenib—CYP2D6—central nervous system—Gilles de la Tourette syndrome	0.00163	0.00187	CbGeAlD
Sorafenib—HTR2C—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0016	0.0125	CbGpPWpGaD
Sorafenib—HTR2B—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00154	0.0121	CbGpPWpGaD
Sorafenib—HTR2C—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00149	0.0117	CbGpPWpGaD
Sorafenib—ABCB1—midbrain—Gilles de la Tourette syndrome	0.00148	0.0017	CbGeAlD
Sorafenib—RAF1—Extracellular vesicle-mediated signaling in recipient cells—MET—Gilles de la Tourette syndrome	0.00138	0.0109	CbGpPWpGaD
Sorafenib—RET—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00132	0.0103	CbGpPWpGaD
Sorafenib—CYP2D6—brain—Gilles de la Tourette syndrome	0.0013	0.00148	CbGeAlD
Sorafenib—HTR2B—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00129	0.0101	CbGpPWpGaD
Sorafenib—RAF1—Signaling of Hepatocyte Growth Factor Receptor—MET—Gilles de la Tourette syndrome	0.00125	0.00982	CbGpPWpGaD
Sorafenib—HTR2C—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00124	0.00974	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling events mediated by TCPTP—MET—Gilles de la Tourette syndrome	0.00123	0.00967	CbGpPWpGaD
Sorafenib—ABCB1—nervous system—Gilles de la Tourette syndrome	0.00122	0.0014	CbGeAlD
Sorafenib—ABCB1—central nervous system—Gilles de la Tourette syndrome	0.00117	0.00134	CbGeAlD
Sorafenib—FGFR1—FGF signaling pathway—MET—Gilles de la Tourette syndrome	0.00108	0.00847	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	0.00108	0.00845	CbGpPWpGaD
Sorafenib—MAPK11—Regulation of retinoblastoma protein—MET—Gilles de la Tourette syndrome	0.00107	0.00843	CbGpPWpGaD
Sorafenib—HTR2C—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00104	0.00819	CbGpPWpGaD
Sorafenib—EPHX2—Metabolism—HDC—Gilles de la Tourette syndrome	0.000951	0.00747	CbGpPWpGaD
Sorafenib—ABCB1—brain—Gilles de la Tourette syndrome	0.000932	0.00107	CbGeAlD
Sorafenib—BRAF—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	0.000893	0.00702	CbGpPWpGaD
Sorafenib—FLT1—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000804	0.00632	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	0.000771	0.00606	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	0.000769	0.00605	CbGpPWpGaD
Sorafenib—ABCC4—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000755	0.00593	CbGpPWpGaD
Sorafenib—RAF1—Regulation of retinoblastoma protein—MET—Gilles de la Tourette syndrome	0.000735	0.00578	CbGpPWpGaD
Sorafenib—BRAF—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.000713	0.00561	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	0.000693	0.00545	CbGpPWpGaD
Sorafenib—UGT1A1—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000653	0.00513	CbGpPWpGaD
Sorafenib—UGT1A9—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000653	0.00513	CbGpPWpGaD
Sorafenib—ABCC2—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000637	0.005	CbGpPWpGaD
Sorafenib—RAF1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—MET—Gilles de la Tourette syndrome	0.00063	0.00495	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	0.000618	0.00486	CbGpPWpGaD
Sorafenib—EPHB6—Axon guidance—MET—Gilles de la Tourette syndrome	0.000572	0.00449	CbGpPWpGaD
Sorafenib—MAP3K7—TGF-beta Signaling Pathway—MET—Gilles de la Tourette syndrome	0.000555	0.00436	CbGpPWpGaD
Sorafenib—MAP2K5—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000549	0.00432	CbGpPWpGaD
Sorafenib—BRAF—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.000546	0.0043	CbGpPWpGaD
Sorafenib—EPHA6—Axon guidance—MET—Gilles de la Tourette syndrome	0.000537	0.00422	CbGpPWpGaD
Sorafenib—KDR—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000535	0.00421	CbGpPWpGaD
Sorafenib—RAF1—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.000493	0.00388	CbGpPWpGaD
Sorafenib—HTR2B—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000468	0.00368	CbGpPWpGaD
Sorafenib—BRAF—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000456	0.00358	CbGpPWpGaD
Sorafenib—HTR2B—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000454	0.00357	CbGpPWpGaD
Sorafenib—HTR2B—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000423	0.00333	CbGpPWpGaD
Sorafenib—RAF1—TGF-beta Signaling Pathway—MET—Gilles de la Tourette syndrome	0.000422	0.00332	CbGpPWpGaD
Sorafenib—EPHB6—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000408	0.00321	CbGpPWpGaD
Sorafenib—HTR2B—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000401	0.00315	CbGpPWpGaD
Sorafenib—PDGFRA—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000393	0.00309	CbGpPWpGaD
Sorafenib—HTR2B—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000389	0.00306	CbGpPWpGaD
Sorafenib—EPHA6—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000383	0.00301	CbGpPWpGaD
Sorafenib—HTR2B—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.000383	0.00301	CbGpPWpGaD
Sorafenib—RAF1—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.000378	0.00297	CbGpPWpGaD
Sorafenib—HTR2C—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000378	0.00297	CbGpPWpGaD
Sorafenib—HTR2C—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000367	0.00288	CbGpPWpGaD
Sorafenib—HTR2B—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000363	0.00285	CbGpPWpGaD
Sorafenib—PDGFRB—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000354	0.00278	CbGpPWpGaD
Sorafenib—KDR—Axon guidance—MET—Gilles de la Tourette syndrome	0.000349	0.00274	CbGpPWpGaD
Sorafenib—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000343	0.0027	CbGpPWpGaD
Sorafenib—HTR2C—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000341	0.00268	CbGpPWpGaD
Sorafenib—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000323	0.00254	CbGpPWpGaD
Sorafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000321	0.00252	CbGpPWpGaD
Sorafenib—RAF1—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000315	0.00248	CbGpPWpGaD
Sorafenib—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000314	0.00247	CbGpPWpGaD
Sorafenib—HTR2C—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.000309	0.00243	CbGpPWpGaD
Sorafenib—HTR2B—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000305	0.0024	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000301	0.00236	CbGpPWpGaD
Sorafenib—HTR2B—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000296	0.00233	CbGpPWpGaD
Sorafenib—HTR2B—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000296	0.00233	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000296	0.00232	CbGpPWpGaD
Sorafenib—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000293	0.0023	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000292	0.00229	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000287	0.00226	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—HDC—Gilles de la Tourette syndrome	0.000281	0.00221	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—HDC—Gilles de la Tourette syndrome	0.000281	0.00221	CbGpPWpGaD
Sorafenib—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000277	0.00217	CbGpPWpGaD
Sorafenib—HTR2B—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000276	0.00217	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000272	0.00214	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000267	0.0021	CbGpPWpGaD
Sorafenib—FGFR1—Axon guidance—MET—Gilles de la Tourette syndrome	0.000257	0.00202	CbGpPWpGaD
Sorafenib—HTR2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000254	0.002	CbGpPWpGaD
Sorafenib—KDR—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000249	0.00196	CbGpPWpGaD
Sorafenib—HTR2C—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000246	0.00194	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000245	0.00193	CbGpPWpGaD
Sorafenib—ABCC4—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000242	0.0019	CbGpPWpGaD
Sorafenib—HTR2C—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000239	0.00188	CbGpPWpGaD
Sorafenib—HTR2C—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000239	0.00188	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—HDC—Gilles de la Tourette syndrome	0.000239	0.00188	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000238	0.00187	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—HDC—Gilles de la Tourette syndrome	0.000237	0.00186	CbGpPWpGaD
Sorafenib—HTR2C—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000223	0.00175	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000222	0.00174	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000221	0.00173	CbGpPWpGaD
Sorafenib—MAPK11—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000214	0.00168	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000214	0.00168	CbGpPWpGaD
Sorafenib—RAF1—Axon guidance—MET—Gilles de la Tourette syndrome	0.000206	0.00162	CbGpPWpGaD
Sorafenib—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000205	0.00161	CbGpPWpGaD
Sorafenib—ABCC2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000204	0.0016	CbGpPWpGaD
Sorafenib—RAF1—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000203	0.0016	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.0002	0.00157	CbGpPWpGaD
Sorafenib—HTR2B—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000193	0.00152	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.00019	0.0015	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000187	0.00147	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000183	0.00144	CbGpPWpGaD
Sorafenib—ABCG2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000177	0.00139	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—HDC—Gilles de la Tourette syndrome	0.000175	0.00138	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000173	0.00136	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—HDC—Gilles de la Tourette syndrome	0.000171	0.00134	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000168	0.00132	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000157	0.00123	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000156	0.00123	CbGpPWpGaD
Sorafenib—HTR2C—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000156	0.00123	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000155	0.00122	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000152	0.0012	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000151	0.00118	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—HDC—Gilles de la Tourette syndrome	0.000148	0.00116	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000147	0.00115	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000147	0.00115	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000146	0.00115	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000146	0.00115	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000142	0.00112	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000142	0.00112	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000142	0.00111	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.00014	0.0011	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000139	0.00109	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000136	0.00107	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000135	0.00106	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000133	0.00104	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000132	0.00104	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—HDC—Gilles de la Tourette syndrome	0.000132	0.00104	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—HDC—Gilles de la Tourette syndrome	0.000129	0.00101	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000126	0.000994	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000126	0.000992	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000126	0.000989	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000125	0.000983	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000123	0.000965	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000123	0.000963	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—HDC—Gilles de la Tourette syndrome	0.000122	0.000956	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000121	0.000954	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—HDC—Gilles de la Tourette syndrome	0.000121	0.000947	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000114	0.000899	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000114	0.000897	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000114	0.000895	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000114	0.000895	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000113	0.000889	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00011	0.000868	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00011	0.000868	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000109	0.000859	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000108	0.000849	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000108	0.000847	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000105	0.000824	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000105	0.000822	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—HDC—Gilles de la Tourette syndrome	0.000103	0.00081	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000103	0.000809	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000103	0.000809	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	9.92e-05	0.00078	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	9.77e-05	0.000768	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	9.74e-05	0.000766	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	9.71e-05	0.000763	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	9.59e-05	0.000753	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	9.54e-05	0.00075	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	9.42e-05	0.000741	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	9.3e-05	0.000731	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	9.28e-05	0.000729	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	9.26e-05	0.000728	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	8.99e-05	0.000706	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	8.82e-05	0.000693	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	8.78e-05	0.00069	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	8.65e-05	0.00068	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	8.4e-05	0.00066	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	8.37e-05	0.000658	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	8.01e-05	0.000629	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	7.99e-05	0.000628	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—HDC—Gilles de la Tourette syndrome	7.95e-05	0.000625	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	7.92e-05	0.000622	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	7.82e-05	0.000615	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	7.47e-05	0.000587	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	7.25e-05	0.00057	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	7.21e-05	0.000567	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	7.21e-05	0.000567	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	6.84e-05	0.000538	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	6.82e-05	0.000536	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	6.75e-05	0.000531	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	6.15e-05	0.000483	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	5.86e-05	0.000461	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	5.48e-05	0.000431	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	4.73e-05	0.000372	CbGpPWpGaD
